tiprankstipranks
Advertisement
Advertisement
Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim
PremiumThe FlyUnicycive Therapeutics price target lowered to $37 from $40 at Guggenheim
24d ago
Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)
Premium
The Fly
Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)
25d ago
Unicycive Therapeutics initiated with a Buy at B. Riley
Premium
The Fly
Unicycive Therapeutics initiated with a Buy at B. Riley
1M ago
Positioning Oxylanthanum Carbonate for Category-Defining Growth via TDAPA Advantage, Regulatory Clarity, and Robust Shareholder Returns
PremiumRatingsPositioning Oxylanthanum Carbonate for Category-Defining Growth via TDAPA Advantage, Regulatory Clarity, and Robust Shareholder Returns
3M ago
Unicycive Therapeutics management to meet with Piper Sandler
Premium
The Fly
Unicycive Therapeutics management to meet with Piper Sandler
4M ago
Unicycive Therapeutics initiated with a Buy at WestPark Capital
Premium
The Fly
Unicycive Therapeutics initiated with a Buy at WestPark Capital
4M ago
Unicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning
PremiumRatingsUnicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning
7M ago
Unicycive Therapeutics Doubles Stock Sale Agreement
Premium
Company Announcements
Unicycive Therapeutics Doubles Stock Sale Agreement
7M ago
Positive Outlook for Unicycive Therapeutics Amidst Promising Developments and Financial Stability
Premium
Ratings
Positive Outlook for Unicycive Therapeutics Amidst Promising Developments and Financial Stability
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100